Abstract | Infections arising from multidrug-resistant pathogenic bacteria are spreading rapidly throughout the world and threaten to become untreatable. The origins of resistance are numerous and complex, but one underlying factor is the capacity of bacteria to rapidly export drugs through the intrinsic activity of efflux pumps. In this Review , we describe recent advances that have increased our understanding of the structures and molecular mechanisms of multidrug efflux pumps in bacteria. Clinical and laboratory data indicate that efflux pumps function not only in the drug extrusion process but also in virulence and the adaptive responses that contribute to antimicrobial resistance during infection. The emerging picture of the structure, function and regulation of efflux pumps suggests opportunities for countering their activities.
Bacterial antibiotic resistance has numerous origins, and several general mechanisms of adaptive responses have been described that give rise to resistant behaviour in bacterial populations 1 . Resistant phenotypes can arise from the boost of intrinsic efflux activity through the overexpression, asymmetric accumulation during division or mutation of genes encoding energy-dependent transporters [2] [3] [4] . Depending on the antibiotic or toxin challenge, efflux can be the fastest acting and most effective resistance mechanism in the bacterial repertoire of stress responses. Exposure to antibiotics and other drugs often triggers very complex bacterial reactions that involve changes in the level of expression of numerous transporter genes, as seen by phenotypic profiling of Escherichia coli 5 . These transporters provide several antibiotic efflux pathways that can work in a cooperative manner or provide redundant functionality 6, 7 . Currently, six families of bacterial drug efflux pumps have been identified that contribute to the efflux pathways. One of these, the ATP-binding cassette (ABC) family, directly utilizes ATP as the energy source to drive transport. The other five groups are secondary active transporters that are powered by electrochemical energy captured in transmembrane ion gradients; they are the major facilitator superfamily (MFS), the multidrug and toxin extrusion (MATE) family, the small multidrug resistance (SMR) family, the resistance-nodulation-cell division (RND) superfamily and the proteobacterial antimicrobial compound efflux (PACE) family 8, 9 ( Fig. 1) . Most of the efflux families have an early origin and have been sustained during the course of evolution, as seen, for example, in the ubiquity of the MFS, MATE and RND families or superfamilies among all domains of life.
The efflux machinery is well tuned to cope with hazardous compounds and harmful metabolic waste products of immensely diverse chemical character.
Currently, about 80% of all severe bacterial infections observed clinically are attributed to multidrugresistant Gram-negative species 10, 11 . These bacteria are characterized by a cell envelope comprising two membranes that function as a barrier to the entry of drugs and other compounds (Fig. 1) . Tripartite efflux pumps span this envelope to drive the efflux of compounds across this barrier. Not all transporters form such assemblies, but the pumps can cooperate as part of a system that moves the efflux substrates first into the periplasm and then outward through a tripartite machine 6, 7 .
Advances in structural analyses of the different classes of transporters have recently provided unprecedented insight into their detailed function (FigS 2,3).
Investigations of pump expression patterns reveal complex regulatory networks at the transcriptional and posttranscriptional level with connections to many cellular processes, including central metabolism. Accumulating evidence suggests that efflux pumps have much broader functional roles during infection, beyond transport of noxious compounds (Box 1). For example, pumps can contribute to bacterial pathogenicity through transport of proteinaceous toxins and other virulence factors, as well as having roles in cell-to-cell communication and formation of protective biofilms. In addition, efflux pumps play a part in lipid transport (in Mycobacteria) and possibly persistence in the presence of antibiotics 12 .
In this Review, we summarize our current understanding of the structures and molecular mechanisms of multidrug efflux pumps in bacteria. We discuss their Multidrug efflux pumps: structure, function and regulation regulation by two-component systems (TCSs) as well as by transcription and post-transcription factors and explore efflux-mediated resistance to antibiotics.
Molecular mechanisms of multidrug efflux ABC transporters. The ABC transporters are functionally diverse and mediate ATP-dependent import or export of solutes. Some function as modulators of ion channels 13 . The structures of ABC transporters reveal transmembrane domains (TMDs) that contain substrate-binding pockets and nucleotide-binding domains (NBDs) that bind and hydrolyse ATP to drive the transport cycle [14] [15] [16] [17] [18] [19] . The ABC exporters can be divided into homodimeric and heterodimeric groups, with the latter being particularly relevant for intrinsic and acquired antibiotic resistance in Gram-positive bacteria (for example, PatAB, LmrCD, BmrCD and EfrCD). Although most homodimeric ABC exporters are thought to have two equivalent nucleotide-binding sites, heterodimeric ABC exporters contain a degenerate binding site that does not support ATP hydrolysis 20 . ATP binding at the degenerate site establishes additional contacts across the NBD-NBD dimer interface and prevents the NBD dimers from fully separating, a molecular feature that might distinguish the heterodimeric and homodimeric ABC transporters. For the heterodimeric ABC exporter BmrCD, the NBDs have been shown to be non-equivalent, conferring an intrinsic asymmetry in the transporter 21 .
The current structural and functional data for both importers and exporters support an 'alternating access' mechanism, whereby the conformation switches states between inward-open, occluded and outwardopen to translocate substrates across the membrane The envelope of Gram-negative bacteria has three principal layers: the outer membrane, the inner membrane and the peptidoglycan cell wall in the interstitial periplasm between the two membranes. In Gram-negative bacteria, all the drug transporters are located in the inner membrane. Structures of representatives of each of the transporter families are presented, including the ATP-binding cassette (ABC), major facilitator superfamily (MFS), multidrug and toxin extrusion (MATE), small multidrug resistance (SMR) and resistance-nodulation-cell division (RND) families. The ABC transporters use ATP to drive transport processes, and the other families depicted use electrochemical gradients for an energy source. The groups differ in architectural features, as described in more detail in the main text. The ligands for the MFS, MATE and SMR representatives are indicated. The RND superfamily drug transporters mostly assemble with their partner proteins to form tripartite pumps, and these bind substrates at the outer leaflet of the inner membrane and periplasm and efflux them to the cell exterior. By contrast, members of the other families of drug transporters usually function as independent units in the inner membrane to translocate substrates across the membrane bilayer. It is likely that these transporter systems cooperate with RND-type tripartite efflux pumps to deliver substrates across the entire cell envelope as part of a larger drug efflux superorganization. The structures of the proteobacterial antimicrobial compound efflux (PACE) class of transporters have not yet been experimentally elucidated and are therefore not included here. Some ABC superfamily and 14-transmembrane helix MFS transporters can also form tripartite pumps and directly transport substrate from the inner leaflet of the inner membrane and cytoplasm to the exterior. The interactions of the tripartite pumps with the peptidoglycan layer are not well characterized presently and are depicted speculatively. AcrAB-TolC and MacAB-TolC are RND-based and ABC-based tripartite multidrug efflux pumps, respectively. Sav1866 Protein Databank (PDB) identifier: 2HYD; MdfA PDB: 4ZOW; DinF-BH PDB: 4LZ9; EmrE PDB: 3B5D; AcrA/B/TolC EM Data Bank (EMDB) entry: EMD-8640; MacA-TolC EMDB: EMD-3652; MacB EMDB: EMD-3653. LPS, lipopolysaccharide.
bilayer (Fig. 2a) . The conformational changes are linked with NBD dimerization and dissociation mediated by ATP binding and hydrolysis [22] [23] [24] . The bacterial homodimeric MsbA uses its ATPase activity to move the lipopolysaccharide precursor lipid A from the cytoplasmic leaflet of the inner membrane to the periplasmic leaflet. This catalytic action confers the enzyme with the descriptive title of 'flippase' . The structures of MsbA in defined functional states have been elucidated by cryo-electron microscopy (cryo-EM) and enabled the visualization of the transport process 25 .
In the absence of ATP, the lipopolysaccharide can be + symport, exchange and counterflow reaction of the major facilitator superfamily (MFS) group. During the symport cycle, the lactose permease LacY symporter binds lactose with high affinity as a result of its protonation (see step 1 for influx reaction and step 6 for efflux reaction). The binding of galactoside (see steps 2 or 5) triggers a conformational switch from an outward-open (influx) or inward-open (efflux) state to an occluded conformation of the dimer (see steps 3 or 4). This is followed by opening up of the dimer towards the respective opposite side inward-open (influx) or outward-open (efflux), the release of the substrate and deprotonation of LacY (steps 1 or 6). At this state, LacY adapts an apo-occluded conformation (see steps 7 or 8). In the case of an exchange or counterflow cycle, LacY undergoes only steps 2-5 (yellow area). An analogous process may occur for the drug-exporting group of the MFS family. c | Cartoon schematics of the transport mechanism of multidrug and toxin extrusion (MATE) transporters. The amino-terminal and carboxy-terminal domains of MATE transporters form a V-shaped central cavity. The structures apparently adopt an outwardopen state with the lower portion of the central cavity situated about halfway through the membrane bilayer. In the Neisseria gonorrhoeae NorM, a drug-binding site has been identified in a central cavity situated near the membrane-periplasm interface (top panel). The substrate and cation (Na + ) interact with distinct subsets of amino acids (the three key residues that are involved in Na + coordination (corresponding to N. gonorrhoeae NorM Y294, E261 and D377) are indicated) and can bind to the protein simultaneously. Therefore, the coupling between the fluxes of Na + and drug is likely to be indirect and mediated by protein conformational changes. The location of the transport substrates rhodamine 6G and ethidium bromide are indicated. Substrates bind more deeply within the central cavity of the DinF subfamily member DinF-BH, where the interactions are mostly mediated by hydrophobic amino acids. For another DinF subfamily member, PfMATE, the drug-binding site is formed exclusively within the amino terminus (N terminus) and is dominated by polar amino acids. The substrate and cation (proton) interact with the same amino acids and compete with each other to bind. The coupling between the fluxes of H + and drug is likely direct (not indicated). The location of transport substrates verapamil and the norfloxacin-derivative substrate Br-NRF are indicated. Pi, inorganic phosphate.
identified in the transmembrane region of MsbA near the periplasm. In the presence of a transition-state analogue that mimics ATP hydrolysis (ADP-vanadate), MsbA assumes a closed state conformation, but when ADP is present, an inward-facing conformation is observed. These structures can be considered as snapshots of the transport process and are consistent with the alternative access model. The bacterial ABC transporter . Another pathway proposed involves channel 2, defined by the PC1 and PC2 subdomains in the pore domain, and directly guides substrates from the periplasm to the proximal binding pocket. Drugs with higher molecular mass, such as rifampicin and erythromycin, favour an access pocket in the L monomer, whereas smaller drugs, such as minocycline and doxorubicin, tend to locate to a deep binding pocket within the T monomer. Pump inhibitors, such as ABI-PP and MBX3132 (not shown), penetrate even more deeply into the T monomer and insert into a hydrophobic chamber (the hydrophobic trap) that branches from the deep binding pocket. The pockets have multiple sites of interactions and can contact different drugs in distinct ways, as seen when comparing the minocycline and doxorubicin complexes (not shown). In an entirely distinct mode of interaction, fusidic acid and other lipophilic carboxylated drugs locate to a groove at the interface between transmembrane helix 1 (TMH1) and TMH2. The polyspecificity of this transporter may be underpinned by the multiplicity of interactions within the pocket and dynamic hydration patterns during the transport process.
McjD exports antibacterial peptides, and structural and spectroscopic data support a mechanism whereby a binding cavity is transiently opened in the outwardfacing conformation, causing release of the peptide 26 . In addition to the conformational changes in ABC exporters facilitated by ATP binding and hydrolysis, a role of electrochemical ion gradients in transport has been indicated by studies of the bacterial homodimeric ABC exporters LmrA 27 and MsbA
28
. By analogy with the chemiosmotic coupling of secondary active transporters, the coupling to electrochemical ion gradients most likely imposes directionality on steps in the transport cycle of ABC transporters that are not regulated by nucleotide. Thus, although bacterial ABC multidrug exporters share protein motifs and common features, the detailed structural differences might translate into a diversity in molecular mechanisms 29 .
Tripartite assemblies involving ABC transporters. In E. coli and other Gram-negative bacteria, the ABC exporter MacB contributes to drug resistance and virulence. In those organisms, MacB forms a tripartite assembly with the outer membrane protein TolC and the periplasmic partner protein MacA. These pumps drive not only the efflux of macrolide antibiotics but also the transport of outer membrane lipopeptides, protoporphyrin, polypeptide virulence factors and lipopolysaccharides. The transport processes are coupled to ATP hydrolysis by MacB.
Cryo-EM structures have been obtained for the MacAB-TolC assembly, which consists of a TolC homotrimer, six protomers of MacA and a MacB homodimer 30 ( Fig. 1) . The 3:6:2 stoichiometry of the assembly is consistent with results from biophysical experiments 31 and the dimer seen in the crystal structure of MacB homologues 32, 33 . The assembly may accept some transport substrates from the periplasm. For example, the precursor of one of its substrates, the heat-stable enterotoxin II 34 , is transported by the general secretory (Sec) machinery into the periplasm, where it undergoes maturation and might subsequently enter the MacABTolC pump through an opening observed in the cryo-EM structure 30, 33 . For substrates that gain access from the periplasmic side, MacB possibly uses an 'outwardonly' transport mechanism proposed for some ABC transporters, whereby the substrate-binding pocket remains in an outward-facing state. The transporters may intercept their substrates from an outward-facing binding pocket, then undergo a conformational change that is coupled to ATP hydrolysis that decreases affinity for the ligand so that it is displaced into the exterior compartment 35, 36 .
Transporters of the MFS. The MFS group is found in all domains of life and is the largest and most diverse family of transporters. The group encompasses uniporters (that move substrates across the lipid bilayer without any coupling ions), symporters (that couple transport with ion-transport in the same direction as substrate) and antiporters (that facilitate the movement of ion and substrates in opposite directions). Most members of this superfamily function as single, monomeric units. They range from 400 to 600 amino acid residues in length and possess 12 or 14 transmembrane helices (TMHs) organized as two domains, each of which is composed of bundles of six helices 37 . The available structural data support an 'alternating access' mechanism for the MFS proteins, whereby the two domains undergo a conformational switch between inward-open and outward-open states during a transport cycle, similar to that described above for ABC transporters. Data for the lactose permease symporter LacY show that the conformational switch for alternating access is triggered by induced fit from ligand binding and that the electrochemical proton gradients control the rate of transport 38 . The key element of the model is that the binding of proton and substrate are ordered and that a ternary complex is formed (Fig. 2b) . The sequence of binding (that is, proton binding followed by subs trate binding or substrate binding followed by proton binding) can differ between various MFS transporters.
Multidrug efflux is conferred by members of the drug:H + antiporters 1 (DHA1) and DHA2 families. The crystal structures of DHA1 proteins from E. coli have been determined in outward-open (YajR), occluded (EmrD) and inward-open (MdfA) conformations [39] [40] [41] . The structural gallery of three different conformational states resembles closely the states captured for the symporters lactose permease LacY and XylE 38, 42, 43 . The common structural architecture of the DHA1 group comprises amino-terminal and carboxy-terminal domains that are linked by a long cytoplasmic amphipathic helix-containing loop. In the substrate-bound structures of MdfA, drugs and inhibitors bind in a central cavity (formed by TMH1, TMH4, TMH7 and TMH10) (Fig. 4c) . DHA2 family homologues, such as YbgG, have similar domain organization to DHA1 proteins, except that the domains are connected by two V-shaped TMHs 44 . A motif (termed motif C) within the TMH5 situated in the interface between the two amino-terminal and carboxy-terminal bundles could participate with other helices to prevent proton leakage. Two conserved acidic residues, E26 and D34, have been identified in motif D of MdfA, and those residues were shown to be involved in proton transfer 45 , although only D34 participates in substrate binding 40 . Spectroscopic data suggest that protonation drives the conformational switch between alternating access states in the antiporters MdfA and LmrP 46 . Moreover, lipid-protein interactions are reported to affect the proton-dependent and substrate-dependent conformational dynamics of MFS transporters (and other classes of pumps) [47] [48] [49] . The transport cycle of MFS proteins seems to involve ordered binding and release of proton and substrate, but the stoichiometry of drug-proton exchange varies between family members 50, 51 . Whereas the DHA2 family transporter exchanges two protons with one substrate, regardless of whether the transported drug is cationic Box 1 | Efflux pumps have diverse biological roles molecular genetic studies support the concept that efflux pumps provide an ancient mechanism to meet the challenge of surviving in environments laden with noxious compounds. For example, Rhizobium etli, a nitrogen-fixating bacterium that forms nodules in roots of Leguminosae, uses the RmrAB major facilitator superfamily (mFS)-based pump to withstand the toxic effects of plant flavonoids 151 . likewise, AcrAB, the paradigm resistance-nodulation-cell division (RND) class pump of the Gram-negative Enterobacteriaceae, confers resistance to bile salts and thus contributes to survival in the mammalian gut 152 . Some species, such as Pseudomonas sp., have up to a dozen different types of RND proteins, suggesting that it is beneficial for the bacterium to have a repertoire of these pumps 153 . efflux pumps are required for colonization and dissemination during host infection by many pathogenic bacteria and can help bacteria extrude innate host defences. This is particularly clear in Neisseria, which uses RND efflux pumps to extrude host antimicrobial fatty acids and antimicrobial peptides. The role of RND pumps in Neisseria sp., Vibrio sp. and Klebsiella pneumoniae in the export of antimicrobial peptides has been established. For Neisseria gonorrhoeae, the mFS efflux pump protein FarAB is implicated in facilitating rectal infection in mice by ridding the bacteria of anti-gonococcal long-chain fatty acids such as linoleic and palmitic acids 154 . Salmonella enterica subsp. enterica serovar Typhimurium mutants of the tripartite assembly AcrAB-TolC have diminished virulence in mice and poultry 147, 155, 156 , and deletion of macAB, encoding components of an ATP-binding cassette (ABC)-type tripartite pump, also results in loss of virulence for S. Typhimurium in mice 157 . In some species, efflux pumps can also actively contribute to infection processes -for example, in the export of virulence factors, such as siderophores used for the acquisition of iron and other required metals. The catechol siderophore vibriobactin is exported by the Vibrio cholerae RND pump vexGH 158 . enterobactin, the strongest binding siderophore known, is exported by the Escherichia coli mFS transporter entS, with 'back-up' transport function provided by AcrB and other RND pumps 159 . Group A and B streptococci internalize haem for chelation of iron 160 , but the haem itself may then be exported 160 . efflux of haem and protoporphyrins also occur in N. gonorrohoeae 161 and E. coli 162 . The multidrug and toxin extrusion (mATe) family member Clbm transports the precursor of the toxin colibactin from the cytoplasm to the periplasmic space in E. coli 54 . efflux pump activity may in some cases be required for host invasion. Subpopulations of Mycobacterium sp. infecting human macrophages showed overexpressed efflux pumps and as a consequence increased tolerance to a range of antibiotics 163 . Although not identified, the efflux substrate might be a host defensive molecule. In some bacterial species, efflux pumps can export signalling molecules involved in quorum sensing, which is a mechanism of cell-to-cell communication that responds to bacterial population density. Quorum sensing controls gene expression at a population level and thereby affects colony behaviour, including virulence and biofilm formation. In the opportunistic pathogen Pseudomonas aeruginosa, the expression of roughly one-tenth of the genome is controlled through quorum sensing 164 . The sensing signalling molecules acyl-homoserine lactones are exported by the RND efflux pump mexAB-oprm 165 , and the efflux systems mexGHI and mexeF-oprN export a precursor of the Pseudomonas quinolone signalling system 166 . Similarly, quorum sensing inhibitors based on non-native N-acylated l-homoserine lactones and derivatives are known to be exported by mexAB-oprm 167 . The mexGHI system also exports signalling molecules for biofilm formation (namely, phenazine precursors) 168 . Inactivation of RND efflux pumps in P. aeruginosa leads to attenuation of virulence, presumably owing to a lack of signalling molecules. Conversely, efflux pump overexpression can also lead to an attenuated phenotype because the signalling molecules cannot achieve the intracellular concentration threshold required to activate the quorum response as well as the potential consequences for cellular energy use 146 . The AcrB pump has a role in the phenomenon of contact-dependent growth inhibition in E. coli that is characterized by the secretion of the toxin tRNA nuclease CdiA and growth arrest upon intercellular contact 169, 170 . Deletion of acrB confers resistance to CdiA 169 , and although it is unclear how AcrB contributes to this phenomenon, the transporter is likely to have some role in CdiA entry.
with one or two charges, MdfA mostly catalyses efflux of electroneutral or monovalent cationic drugs by exchanging a single proton with a single drug molecule. MdfA also transports divalent cations with two charged moieties separated by a long linker; however, the export of such a cation drug molecule needs two consecutive transport cycles 50 . MdfA shows an indirect competition mechanism between H + and substrates 45 , whereas both direct and indirect mechanisms of competition might be relevant to the case of LmrP 51 .
Although MFS transporters generally function as monomers, some family members are fusions of two homologous but distinct MFS permeases. A recent crystal structure of the plant nitrate transporter 1.1 reveals a homodimer and suggests that the protomers have different affinity modes 52 . In Gram-negative bacteria, some DHA2 family proteins can form tripartite assemblies with partner proteins to directly transport drugs across the entire cell envelope 53 .
MATE transporters.
The MATE transporters can be categorized into the NorM, DinF (DNA-damageinducible protein F) and eukaryotic subfamilies on the basis of their amino acid sequence similarity. Bacterial MATE transporters use transmembrane H + and/or Na + gradients to drive the efflux of polyaromatic and cationic drugs. The structures of NorM and DinF subfamily members reveal two bundles of six TMHs [54] [55] [56] [57] in which the topology is distinct from that seen for the MFS transporters 58 . There are amino-terminal and carboxyterminal domains related by pseudo-twofold symmetry that form a V-shaped central cavity open to the extracellular space. The structures apparently adopt an outwardopen state with the lower portion of the central cavity situated about halfway through the membrane bilayer. NorM may use an alternative access transport mechanism, as indicated by the proximity of residue pairs in vivo 59 . In the structure of Neisseria gonorrhoeae NorM, a drug-binding site has been identified in a central cavity situated near the membrane-periplasm interface (FigS 2c,4d ). The interaction with the substrate is largely mediated by ionic and hydrogen bonding 56, 60 . Three key residues that are involved in Na + coordination (corresponding to N. gonorrhoeae NorM Y294, E261 and D377) are highly conserved in the NorM and eukaryotic subfamilies and probably participate in the transport process 60 . Vibrio cholerae NorM can use both H + and Na + gradients to transport substrates, and an aspartate (residue D371 in V. cholera NorM) has been identified to be involved in proton coupling 61 . The substrate and cation interact with distinct subsets of amino acids and can bind to the protein simultaneously 62 ; therefore, the coupling between the fluxes of Na + and drug is likely to be indirect and mediated by protein conformational changes. As the drug-binding pocket is proximal to the periplasmic side and is inaccessible in a presumptive inward-open state, the protein must adopt a different conformation to recognize substrates from the cytoplasmic side.
For the DinF subfamily member DinF-BH, substrates can be deeply bound within the central cavity, where the interactions are mostly mediated by hydrophobic amino acids 56, 63 (Fig. 2c) . Residue D40 in DinF-BH makes charge-charge interactions with cationic substrates, and evidence indicates that protons directly compete with this interaction 63 . DinF-BH was also captured in an asymmetric outward-open state, in which the pseudotwofold symmetry is broken by the kinking of TMH7 and TMH8 (reF. 63 ). For another DinF subfamily member, PfMATE, the drug-binding site is formed exclusively within the amino-terminal domain and is dominated by polar amino acids (Fig. 2c) . The TMH1 of PfMATE might undergo protonation-dependent bending, but its function in the transport cycle and generality to other family members is not clear 56, 57 . The currently available structures of MATE transporters are all captured in an outward-facing state. The intracellular-facing state may resemble the inward-facing conformation of the structurally related lipid II flippase MurJ 64 , a member of the newly defined supergroup that includes the MATE proteins (referred to as the multidrug oligosaccharidyl-lipid polysaccharide (MOP) transporter superfamily in the transporter classification database). Obtaining the structure of an intracellularfacing state with substrate bound would substantially advance our understanding of MATE-mediated multidrug extrusion.
RND transporters.
The well-characterized Gramnegative members of the RND family include E. coli AcrB, Pseudomonas aeruginosa MexB, Neisseria gonorrhoeae MtrD and Campylobacter jejuni CmeB, for which high-resolution structures are available [65] [66] [67] [68] [69] [70] . The RND proteins are relatively large in comparison to other bacterial membrane proteins, and the members of this superfamily form mainly homotrimers (Fig. 3a) . The ubiquitous RND superfamily also includes members with different quaternary structures, such as the monomeric eukaryotic NPC1 (reF. 71 ), which is involved in cholesterol homeostasis, heterodimeric SecDF, which is part of the protein export complex 72 , and homodimeric HpnN, which shuttles hopanoids to the outer membrane 73 . All RND transporters have a rather atypical structure for the secondary transporter group and display a conserved transmembrane region structure as well as a periplasmic and luminal domain that compose up to 60% of the mass of the protein (see, for example, AcrB in Fig. 1 ). The RND TMDs contain an internal structural repeat that originated through a gene duplication event, whereas the fold of the periplasmic luminal domain can differ substantially among the RND homologues.
Aside from their physiological relevance to the conferment of antibiotic resistance, the molecular mechanism of drug polyspecificity, the movement of the drug through the protein, the coupling of proton and drug antiport (that is, energy transduction) and the dynamics of the assembly and disassembly of the Gram-negative tripartite systems are the most prominent questions. The bacterial RND protomer is central to these questions and comprises three larger domains: the TMDs, the pore domain and the docking domain that engages a periplasmic partner in cases when the RND protein is part of a tripartite assembly (Fig. 1) . The TMD consists of 12 α-helices and is the conduit for proton movement, which is coupled to drug efflux in the pore domain 67, [74] [75] [76] . The pore domain is the main location of drug entry and consists of the subdomains PN1 and PN2, which extend into the periplasm (between TMH1 and TMH2), and PC1 and PC2 (which lie between TMH7 and TMH8) 67, 74 ( Fig. 3a; Supplementary Fig. 1 ). These four subdomains form the two main drug-binding cavities: the proximal (or access) and distal (or deep binding) pockets. Each is enriched with a variety of aromatic, charged and polar residues thought to confer each pocket with slightly different substrate preferences (see for example Fig. 4a,b) . The docking domain consists of the DN and DC subdomains, and its interaction with the periplasmic protein will be discussed further in the subsection on the tripartite assemblies.
AcrB undergoes marked conformational change upon drug binding. Although the protomers of the AcrB trimer are symmetric in the apo state, they have different conformations when actively engaged with substrate: the loose (L), tight (T) and open (O) states 74, 77 . It is thought that these conformations represent three states in drug efflux and that each protomer cycles through these states consecutively, with a high degree of cooperativity 4 ( Fig. 3a; Supplementary Fig. 1 ). The exact details of the process remain to be elucidated, but in brief the model holds that drugs are introduced in the L state, move further into the drug-binding pocket in the T state and then are extruded into a funnel-shaped 'canyon' in the docking domain in the O state 77 . The conformational changes occur in an apparently strict order, with drugs moving further into the protein but unable to leak back into the periplasm; this has been called a 'peristaltic' mechanism in analogy to the physical process 77 . The movements between the PN2 and PC1 subdomains in the L-to-T transition constitute the opening and closing of the distal binding pocket, whereas the PN1 and PC2 subdomains seem to move as a rigid body 76 . The relative movement of the PN2 and PC1 and PN1 and PC2 subdomains in the T-to-O transition closes the periplasmic entry pathway and as such prevents the reverse flow of drugs to the periplasm. The intrinsic and asymmetric interprotomer interaction of the PN1 and PN2 subdomains supports the consecutive and cooperative drug transport model, which is also found to be consistent with functional dependencies of the protomers in the heterotrimeric E. coli MdtBC pump 78 . Therefore, it is a surprising finding that the three protomers of the C. jejuni homologue CmeB seem to undergo conformational switches independently during the efflux process in the microsecond to second time range, as determined by fluorescence energy-transfer measurements 70 . Structures of AcrB bound to different substrates illustrate the surprisingly diverse range of compounds that the transporter can efflux 54, 66, 68, 74, 76, [79] [80] [81] [82] . These structures show slightly different substrate preferences between the proximal and distal binding pockets, possibly also based on the substrate size or minimal projection areas 81, 83, 84 , and are thought to represent, at least for the high-molecular-mass substrates, a progression of drug entry into the proximal pocket during the L state and movement of drug into the distal pocket during the L-to-T transition (Fig. 3b) . A short switch loop is located between the two binding pockets of AcrB that seems to regulate drug entry into the distal pocket 66, 68 . The distal pocket seems to be a universal binding site for the known AcrB drugs. This binding site consists of mainly phenylalanine but also isoleucine, valine, alanine and asparagine side chains (Fig. 4a) . The pocket represents a hydrophobic pit and seems to accommodate all the known substrates. Although the co-structures show binding of single drugs to this pocket, it is not known whether the pocket might bind different (smaller) drugs concomitantly. If so, it might provide one of the explanations for the strong cooperativity of drug transport observed 85 . Water molecules, found to stabilize the binding of substrates and inhibitors 66, 79 , have also been postulated to be involved in drug transport by assisting substrate-protein interactions in a way that is compatible with the polyspecificity of AcrB 86 . Apart from the periplasmic entry pathway, which includes the proximal pocket in the L protomer and further transport towards the distal binding pocket, other pathways have been proposed using channels or tunnels located at the membrane-periplasmic boundary (Fig. 3b) . One channel leading to the distal binding pocket (tunnel 1) is preceded by a major groove comprising TMH7, TMH8 and TMH9, and in most structures a dodecyl maltoside molecule is deeply bound inside 68, [87] [88] [89] . Channel 2 is defined by the PC1 and PC2 subdomains in the pore domain and directly guides substrates from the periplasm to the proximal pocket. This channel seems to be present in both L and T protomers, but the PC1-PC2 cleft seems more closed in the latter protomer. Drugs originating from the periplasm are thought to enter AcrB through this channel 50, 52, 68 . A third channel has its entry from within the central cavity formed by the three protomers within the trimer 67, 68, 90 . This channel was shown to have a preference for planar, low-molecular-mass, cationic aromatic compounds such as ethidium 90 . These substrates are suggested to be directly transported to the distal binding pocket, bypassing the proximal binding pocket and the switch loop. Other substrates, such as the high-molecular-mass macrolides, are preferentially taken up via channel 2. More channels might be present, as carboxylated drugs (such as β-lactams) bind to the TMH1-TMH2 groove 53, 69 , which does not show a defined channel entrance in any of the conformations but is close to the entrance of channel 3 (reF. 90 ). One hypothesis holds that the drug-bound TMH2 moves in different conformational sub-states as a type of 'elevator mechanism' to deliver the transport substrate to the periplasmic pore domain 69 . It is interesting to note that an analogous channel for substrate transport has been proposed to occur for the HpnN transporter, which shuttles hopanoid molecules to the outer membrane of Gram-negative Burkholderia sp., modifying the fluidity of the outer membrane 73 . The transport substrates for AcrB, MexB and other RND transporters encompass diverse compounds that have some lipophilic character but can also harbour moieties that are cationic, neutral (chloramphenicol and solvents) or acidic (β-lactams). Can the structural basis for such broad polyspecificity be rationalized? A recent study on the differences between the AcrB and AcrD binding pockets 91 , known to accept preferentially lipophilic and hydrophilic molecules, respectively, indicated that besides the higher lipophilicity of the AcrB binding pocket, the distal binding pocket in AcrD has a higher hydration tendency, and these water molecules could facilitate binding of hydrophilic drugs; a similar effect is seen in Salmonella enterica subsp. enterica serovar Typhimurium AcrB by G288D substitution 2 . Moreover, simulations also indicated that dynamics of the loops, found especially in the proximal pocket, are different in both proteins and may infer induced-fit-like binding. The binding of drugs to the pocket of RND transporters shares certain features seen in crystallographic studies of MDR pump transcription regulators, such as QacR 92 . For those regulators, activating ligands bind in a large pocket enriched with aromatic side chains, similar to what is seen for the RND transporters. The distal binding pocket of the RND transporters is comparatively large, and different ligands prefer different areas of the pocket for binding. Transport substrates with hydrophilic groups tend to bind to the region of the pocket that is enriched with hydrophilic and charged residues, but hydrophobic ligands such as cyclohexane or chloramphenicol tend to be excluded in these binding pockets.
The general principle that might account for polyspecificity is that hydrophobic drugs do not require small, shape-complementary interaction surfaces in the multidrug transporters or their regulators to form favourable interactions because the ligands are not strongly stabilized in bulk solvent and do not require extensive desolvation. By contrast, in the case of the RND transporters, many of the hydrophobic drugs will most likely reside in the outer leaflet of the inner membrane and enter the periplasmic pore domain via the channels (channels 1 and 3). Compounds with hydrophobic moieties that are likely to partition spontaneously into the bilayer seem to be good substrates of the pump, whereas compounds with hydrophilic side chains are apparently not pumped out efficiently 93 . For the amphipathic substrates, side chain interactions might stabilize first contact to the channel entrance, and the hydrophobic moieties can exert favourable binding energies to small regions of large surfaces, similar to that of the distal binding pocket, so that a broad range of ligands are accepted with only small differences in binding free energies 94 .
Tripartite assemblies involving RND transporters. In E. coli, AcrB forms a tripartite assembly, the AcrAB-TolC efflux pump (Fig. 1) . Homologous RND-based assemblies occur throughout the group of Gram-negative bacteria, and the AcrAB-TolC pump shares some similarities with the MacAB-TolC pump. The cryo-EM structures of the AcrAB-TolC assembly in the drug transport state reveal that the TolC channel is open and is likely to remain open when the pump cycles through three distinct conformations. In the context of the complete pump assembly, the AcrB trimer adopts asymmetric LLT, LTT or LTO conformations in the presence of transportable ligands 80 . As described above, ligand binding to AcrB is associated with large conformational changes for both the PN1 and PC2 and the PN2 and PC1 structural modules that form the drug-binding pocket 76 , but the interfaces between TolC and AcrA, and between AcrA and AcrB, do not change considerably in the different transport states.
In contrast to the drug-bound forms of the pump, in the apo form TolC is sealed closed, and this probably represents a resting state or an early assembly state. A proposed quaternary structural switch couples and synchronizes the initial binding of ligand with channel opening by long-distance communication through allostery 81 . Quaternary structural changes in AcrB associated with drug binding leads to repacking of the helical hairpin domains of AcrA into a configuration that can optimally fit to the open state of TolC. The structural change of AcrA is critical to seal the gaps in the pump, which would otherwise provide a route for substrates to leak into the periplasm. These conformational changes are accompanied by a contraction of the pump along the long axis in its transport state by nearly 10 Å that must entail a local compression of the periplasm and a local curvature of the outer membrane and inner membrane near the portal of AcrB. These changes are likely to influence the energetics and kinetics of the transport process.
SMR and PACE family transporters.
The SMR family proteins confer resistance against quaternary ammonium compounds and other lipophilic cations in archaea and bacteria. They are indeed small, having only four TMHs, but function as homodimers or heterodimers 95 ( Fig. 1) . A representative family member is EmrE, and structural analyses of the E. coli protein by X-ray crystallography, cryo-EM and NMR reveal an architecture of protomers arranged with antiparallel orientation to form an asymmetric dimer [96] [97] [98] , with the two possible configurations occurring at roughly equal frequencies 99, 100 . Four TMHs from each protomer are arranged pairwise across the dimer interface. The first three TMHs form a substrate-binding chamber, whereas the fourth helix is mainly involved in dimerization interactions. The loop connecting TMH3 and TMH4 forms a β-strand structure, which holds TMH4 close to the substrate-binding chamber [96] [97] [98] . During the transport process, the pump alternates between inward-facing and outward-facing states through conformational exchange of the two protomers. Therefore, the two states are identical except that they have opposite orientation in the membrane 98 . Such global conformational motions are modulated in an allosteric fashion by protonation (of E14 in TMH1), which causes extensive rotation and tilt of TMH1, TMH2 and TMH3 in conjunction with repacking of loops 101, 102 . Substrate properties affect the transport rate of the pump, and single-residue substitution in the drugbinding chamber could change the specificity of SMR pumps 103, 104 . Although SMR-like, the Acinetobacter chlorhexidine efflux protein (AceI) has recently been identified as a member of a novel family of multidrug efflux pumps termed the PACE family 9 . AceI and its homologues were shown to contribute to resistance against various synthetic bactericidal agents (chlorhexidine, acriflavine, proflavine and benzalkonium). AceI has a similar size and predicted secondary structure to SMR family members and shares the conserved glutamic acid residue in TMH1 (reF.
8
). The lack of PACE protein-encoding genes in the E. coli chromosome suggests that these genes were lost early after the divergence from other gammaproteobacteria.
Drug efflux pump regulation
The association of efflux with drug resistance was first reported nearly 4 decades ago. To confer effective drug resistance, efflux must match or exceed the rates of influx, and this in turn depends on the composition of the cell envelope and the access to conduits for drug entry, such as porins or other routes 4 . Indeed, porin loss is one mechanism that can confer resistance and has been observed to develop during the course of therapy 4 . There have also been numerous reported cases of efflux-mediated resistance in clinical isolates (TaBle 1) , some of which are associated with overexpression of pumps 105 .
Understanding the regulation of efflux is important as alterations in the regulatory system, such as mutations in the local and global transcriptional regulators, lead to overexpression of efflux pumps. Efflux regulation can differ between species, and even within a species depending on cellular physiological status. The regulation is complex and highly interconnected, and inhibition or deletion of one pump can result in expression of others. For example, the deletion of acrB results in potentially compensating overproduction of AcrD and AcrF 105 . Thus, efflux pump networks complicate the interpretation of resistant phenotypes.
Regulation by two-component systems. Bacteria sense and respond to various environmental stimuli, including stress associated with drug action, using TCSs, which contribute to the adaptive responses that confer drug resistance (Fig. 5) . The systems comprise a sensor histidine kinase and response regulator, and they can be found in many organisms from all domains of life. The histidine kinase and response regulator together function to link signal detection and the generation of the appropriate cellular response (Fig. 5a) . A few studies reported that the histidine kinase senses the antibiotic directly through binding, such as VanS, which directly interacts with vancomycin 106 , but in most cases sensing seems to be indirect. An interesting example is provided by the mechanism of bacitracin resistance in Bacillus subtilis: the bacitracin efflux ABC transporter BceAB itself functions as the sensor by communicating its transport activity to the histidine kinase BceS through protein-protein interaction 107, 108 . In terms of molecular organization, the membraneassociated sensor histidine kinase functions typically as a homodimer and consists of a sensor module, a TMD and one or several intracellular signal transduction domains (such as HAMP, PAS or GAF) as well as an intracellular catalytic core, which comprises a dimerization and histidine-phosphotransfer (DHp) domain and a catalytic ATP-binding (CA) domain 109, 110 . The response regulator protein generally contains a conserved amino-terminal receiver (REC) domain and a highly diverse carboxyterminal effector domain. The response regulator proteins can be divided into five classes according to how the effector domain exerts its response -namely, DNA binding, RNA binding, enzymatically active, protein binding and single-domain effector 110 . Some TCSs, such as CpxAR in Enterobacteriaceae, AdeSR in Acinetobacter baumannii and AmgRS in P. aeruginosa 111 , regulate the expression of multidrug resistance efflux pumps. Mutations in adeSR were found in numerous clinical isolates of A. baumannii 112 and are associated with overexpression of the RND pump AdeAB 112, 113 . The response regulator component AdeR activates adeABC expression by binding to a direct-repeat motif in the intercistronic region 114 , and mutations in adeR lead to enhanced efflux activity of AdeB 115 . AdeSR regulates not only the expression of the tripartite pump system encoded by ade-ABC but also genes for biofilm formation and virulence 116 . Interestingly, TCSs can regulate more than one type of pump, such as in the case of BaeSR in A. baumannii, which is proposed to indirectly regulate AdeAB and AdeIJK RND Fig. 5 | Regulation of efflux pumps. a,b | Cartoon schematics of the regulation by two-component systems. a | Drug binding induces a conformational change in the periplasmic sensor domain. This conformational change is transduced downstream to activate the catalytic core, which autophosphorylates at a conserved histidine residue in the dimerization and histidine-phosphotransfer (DHp) domain. The phosphoryl group is then transferred from the phosphorylated histidine residue to an aspartic acid residue of the response regulator resulting in its activation. b | For the DNA-binding response regulator subfamilies, the activated response regulator generally forms a homodimer, which binds to a specific DNA-binding motif and activates the transcription of target drug transporter genes. c | Complex transcriptional regulatory network of efflux pumps. Expression of acrEF and acrAB is repressed by AcrS. acrAB is also repressed by the local repressor AcrR . The global regulators Rob, SoxS and MarA activate the expression of acrAB, tolC and micF. In Salmonella enterica and Klebsiella pneumoniae, global regulator RamA also activates expression of acrAB. Global regulators are targeted by the ATP-dependent, selective protease Lon. Mutations in Lon result in increased AcrAB-mediated efflux due to loss of degradation of global regulators. Other regulators include the histone-like nucleoid structuring protein (H-NS) (repressor) and the SdiA (activator). acrAB and tolC expression is also controlled by the two-component regulatory systems EvgAS and/or PhoQP. The micF transcript inhibits the translation of OmpF mRNA. ompF transcription is also regulated by several phosphorylated OmpR proteins, which bind in hierarchical order to discrete positions on the DNA according to the galloping model 171 . SoxS and Rob can also stimulate MarA expression. Repressor inactivation can be achieved by ligand binding (for example, antimicrobial agents and metabolites) or oxidative stress induction (see MarR , SoxR and AcrR). Some regulators can also be activated upon ligand binding (for example, Rob is activated through binding of bile salts or fatty acids). Expression of acrZ is co-regulated with the expression of acrAB via MarA , SoxS and Rob
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. CsrA increases expression of AcrAB by binding to the 5′-end of the acrAB transcript. This interaction stabilizes the mRNA and favours its translation. Red lines symbolize transcription repression by the repressors AcrR , AcrS, H-NS, MarR and SoxR . Blue lines indicate activation of relevant gene expression by the activators MarA , SoxS, SdiA , Rob, EvgS, CsrA and PhoP. d | Regulation of efflux pumps by small regulatory RNAs (sRNAs). sRNAs regulate antibiotic resistance genes in numerous ways. Binding of sRNAs to the ribosome-binding site (RBS) can repress translation. sRNAs can also induce mRNA degradation by binding to a specific cognate site in the transcript and recruiting ribonuclease. In addition to repressor functions, sRNAs can promote translation by preventing the formation of inhibitory secondary structures. Regulatory RNA can also occur in cis-acting elements 128 . Antibiotic-triggered RNA-mediated regulation is common in the bacteria of human commensal species and pathogens and includes most classes of resistance genes, including several predicted classes of multidrug antibiotic efflux pumps and exporters efflux pumps and the MacAB ABC pump and has been suggested to increase resistance to tigecycline. Similarly, in S. Typhimurium, BaeSR regulates the expression of AcrD and MdtABC RND pumps 117 . In E. coli, 15 TCSs have been identified that contribute to drug resistance, 5 of which modulate the expression of drug efflux pump genes. The E. coli BaeSR and CpxAR systems activate the expression of mdtABC and acrD in response to indole and envelope stress, respectively. The two-component EvgAS system controls the expression of mdtEF, emrKY, acrAB, tolC and mdfA, but the triggering stimuli are currently unknown 4, 118 . Expression of the TolC outer membrane channel is also affected by another TCS, PhoPQ.
Structural and functional data have advanced the mechanistic understanding of TCS systems. The crystal structures of E. coli nitrate/nitrite sensor NarQ provide a direct demonstration of signal transduction through the TMD and HAMP domains 109 . Ligand binding to the sensor domain causes piston-like shifts of TMHs, which are accompanied by extensive rearrangements. The HAMP domain protomers undergo lever-like motions and convert the piston-like movements of the TMHs into helical rotations. It is presently unclear how this conformational change transduces downstream of the HAMP domain to activate the catalytic core. The structure of the HK853-RR468 complex from Thermotoga maritima reveals the communication between the histidine kinase and response regulator, during which a phosphoryl group is transferred from phosphorylated H260 in the HK853 catalytic core to D53 of RR468 and thereby activates RR468 (reF.
119 ) (Fig. 5a ). The signal-activated HK853 autophosphorylates the conserved H260 in the DHp domain. The RR468 dimer docks onto the DHp domain and catalyses its own phosphorylation at D53 www.nature.com/nrmicro using the phosphorylated histidine as a substrate. For the DNA-binding response regulator subfamilies, the activated response regulator can form a homodimer that binds to a specific DNA-binding motif and activates the transcription of the target drug transporter gene (Fig. 5b) .
Regulation by transcription and post-transcription factors. Clinical isolates of drug-resistant bacteria have been found to contain genomic mutations in transcriptional repressors and in the promoters of the genes encoding the RND and ABC transporters. Mutations in genes encoding local regulators, such as the tetra cycline repressor protein (TetR) family of transcriptional repressors (for example, emrR, acrR and mtrR) [120] [121] [122] [123] , or overexpression of global transcriptional regulators, including AraC-XylS transcription factors (for example, MarA, SoxS and RamA), result in overexpression of efflux pumps and increased transport activity. Although rare, some N. gonorrhoeae isolates carry mutations in the mtrA global regulator gene, resulting in a lack of overexpression of the MtrCDE RND efflux pump 124 . The AcrB RND transporter is encoded in the acrRAB operon, for which AcrR functions as the local repressor (Fig. 5c) . Mutations in acrR lead to overexpression of AcrAB and have been described in clinical and veterinary isolates resistant to the AcrB substrate fluoroquinolone 4 . AcrR is one of many regulators of the operon; examples of other regulators are Mar, RamA, Sox and Rob (see below). AcrB overproduction in Klebsiella sp. and Salmonella sp. is also caused by mutations in ramR and in soxR 4 . In the same way in which the expression of one pump is controlled by multiple regulators, it has also been shown that one regulator can control the expression of multiple pumps. For example, MarA in E. coli regulates the expression of AcrAB-TolC and is also involved in regulation of the ABC transporter encoded by the mlaFEDCB operon 125 . The transcription of acrAB and tolC genes encoding the tripartite assembly is controlled by many regulators, including MarA, RamA, SoxS and Rob. These are transcription factors that bind to the marbox, a degenerate sequence of approximately 20 base pairs found in multiple promoter sequences. These factors can activate the transcription of multiple genes, including those encoding efflux pumps and porins. Together, the different regulatory mechanisms can give rise to multidrug resistance by decreasing influx through suppression of the expression of the OmpF porin while increasing efflux mediated by AcrAB-TolC.
The ArmZ-MexZ system functionally links the activation of the pump with ribosome activity, and at least two signal transduction regulatory systems interconnect MexXY-OprM or MexXY-OprA with other cellular processes. Transcriptional attenuation is another mechanism that is involved in regulating some antibiotic efflux pumps 4 . Post-transcriptional processes are involved in finetuning regulation of gene expression and are likely to be involved in controlling antibiotic susceptibility and efflux pump expression 126, 127 . The recent discovery of antibiotic-responsive riboswitches from studying changes in RNA levels in bacterial communities has highlighted a key regulatory role of RNA in the emergence of resistance 128 . Expression of efflux pumps can be regulated by attenuation through cis-encoded RNA elements as a primary regulatory mechanism. In these cases, the antibiotics target the ribosome and cause stalling when translating a short leader peptide upstream of the resistance gene. As a result, RNA secondary structure is changed and the resistance gene can be translated or transcribed (depending whether translation or transcription termination is regulated by attenuation) 128 .
Trans-acting small regulatory RNAs (sRNAs) (Fig. 5d) are also likely to have important roles in efflux regulation, as suggested by the phenotype of strains that are defective for expressing the RNA-binding protein Hfq that is a chaperone for sRNAs. Such mutants are not only attenuated in virulence but are also more susceptible to many antibiotics 123 . There are at least three known mechanisms of efflux pump regulation by sRNA. In one such case, sRNA can repress translation by blocking the ribosomebinding site through binding to the latter. sRNA can also promote mRNA degradation through its specific binding to a cognate site in the transcript and via recruitment of ribonucleases. In addition to its repressor function, sRNAs are able to promote translation (activator function) by preventing the formation of inhibitory secondary structure in the target mRNA. Some notable examples are the sRNA SdsR, which binds and represses the tolC mRNA in E. coli 129 , and DsrA, which regulates expression of MdtEF, albeit indirectly 130 . In N. gonorrhoeae, expression of MtrF (a component of MtrCDE) is regulated by sRNA NrrF 131 . sRNAs can contribute to 'rewiring' TCSs and linking these with other processes and can thereby affect the expression of efflux pumps 132 . These regulatory RNAs can also regulate numerous processes related to virulence 129, 130 . In principle, compounds that target such riboregulators could affect antibiotic resistance and could be useful leads for drug development.
Regulation of AcrB by a small protein. Small proteins have been discovered in various organisms that can have important biological roles. Often overlooked in genome studies, these small proteins affect spore formation and cell division, regulate transport, membrane-bound enzymes, protein kinases and signal transduction, and function as chaperones, among other functions 133 . There are approximately 60 confirmed small proteins in E. coli 134 . They are often expressed under specific conditions, and many are thought to modify the activity of large membrane proteins 134 . E. coli AcrZ is a 49-amino-acid small protein that interacts with and regulates AcrB 134 . Deletion of acrZ results in sensitivity to some but not all of the antibiotics for which AcrB provides resistance 134 . This finding indicates that AcrZ has a role in substrate recognition or AcrB regulation. Indeed, AcrB and AcrZ are coregulated by the transcription factors MarA, Rob and SoxS, supporting a key functional role for the small protein 134 . Structural studies of the AcrBZ complex by X-ray crystallography and in the context of the full pump assembly (by cryo-EM) indicate that AcrZ forms a helix that interacts with AcrB in the transmembrane portion 80, 135 . Perhaps AcrZ and other related peptides might exercise allosteric effects on their RND partners to modulate efflux activities.
Efflux-mediated resistance to antibiotics Whole-genome sequencing case studies suggest that adaptive evolution within the host has an important role in bacterial infections 136 . Sub-lethal doses of antibiotics can trigger numerous processes that enable bacteria to survive antibiotic exposure. Epigenetic effects have been proposed to play a part in upregulating efflux transporters. The observed phenomenon of persistence, whereby a subpopulation of bacteria that may be metabolically quiescent survives initial exposure to antibiotic although they may be genetically identical to the drug-susceptible group, may complicate strategies for treatment 137, 138 . It is interesting to note that in E. coli, persister cells have been proposed to have enhanced efflux activity and lower intracellular antibiotic concentrations 12 . The persistent subpopulation might be greater in a biofilm 139 . Efflux pumps also have a role in the establishment of heteroresistance, which is characterized by subpopulations of bacteria that have a resistant phenotype, conferring clinical levels of resistance to the isolate.
In many cases, MDR clinical isolates of bacteria exhibit multiple mechanisms of resistance 4 . For example, fluoroquinolone-resistant MDR E. coli were found to have increased efflux, decreased permeability and a mutation that decreases gyrase sensitivity to the drug (GyrA S83L) 140 . Similar findings were made for fluoroquinolone-resistant S. enterica serovars 141 and strains of Mycobacterium tuberculosis 142 resistant to quinolones and other drugs. For example, mutations in inhA or katG confer resistance to isoniazid in M. tuberculosis 142 
.
Overexpression of efflux pumps is one mechanism that can contribute to multidrug resistance. Redirecting protein synthesis to make efflux pumps is metabolically demanding; thus, it is perhaps not surprising that a metabolic cost can be associated with drug resistance 143 . Changes in various metabolic processes have been observed with overexpression of RND-based pumps in mutants of N. gonorrhoeae MtrCDE 144 , MexAB and P. aeruginosa MexXY-OprM 145 , MexEF-OprN and MexCD-OprJ 146 . Overexpression of the AcrB RND pump, in response to a high concentration of chloramphenicol, drives central carbon metabolism from an oxidative state to a fermentative one 143 and may compensate for the stress induced by overexpression 145 . In this regard, it is important to note that efflux pump gene-deletion mutants may not be the best model to study the physiological role of pumps as there are notable transcriptome differences between a S. Typhimurium ΔacrB and an AcrB D408A mutant 147 . The AcrB D408A mutant expresses the inactive protein that lacks efflux function (and was found to be attenuated in multiple infection models). Importantly there was no increased expression of homologous RND efflux pumps (in comparison to the ΔacrB mutant strain). This finding suggests that the compensatory role of these proteins is fulfilling a structural requirement rather than an efflux function.
Although overexpression of pumps might confer drug tolerance, too much overexpression can in some cases be detrimental to the fitness and virulence of the bacterium, as seen for instance in a S. Typhimurium mutant overexpressing AcrAB 148 . Similarly, a P. aeruginosa mutant overexpressing MexEF was shown to be less virulent in a Caenorhabditis elegans infection model. However, there is no simple rule relating expression and fitness, as shown by the finding that a Klebsiella pneumoniae mutant overexpressing AcrAB, via deletion of the transcriptional regulator ramR, had increased virulence in a mouse infection model 149 . Furthermore, overexpression of the MtrCDE RND-based efflux pump in N. gonorrhoeae led to increased fitness in a mouse model 144 . Mutations in pumps is a potential mechanism to alter activity, and mutated binding pockets in AcrB have been observed to confer clinically relevant MDR that evolved in a patient during treatment of an infection by S. Typhimurium. A G288D substitution changed the substrate specificity of the pump, conferring ciprofloxacin resistance 2 . In drug-resistant clinical isolates of C. jejuni, mutations in the drug-binding pocket of the RND transporter CmeB have been identified 150 , which map to the corresponding drug-binding pocket of AcrB 68, 74 .
Conclusions and perspectives
Structural studies of transporters and their assemblies have provided insights into the molecular origins of MDR. The mechanisms of the transporters -how they transduce energy to drive translocation of substrateshave advanced for the main classes of these proteins. In Gram-negative species, the transporters function as a coordinated network, in which the final step of efflux is achieved by a tripartite assembly. Similar systems are likely to contribute to resistance and survival in mycobacterial pathogens. These advances are complemented by improved understanding of the numerous biological roles of pumps beyond simple transport, such as the contribution of bacterial efflux pumps towards virulence and community behaviour. Future efforts to explore the dynamics of pump assembly and the interplay between transporters and transporter components include the regulation of expression of the different components controlled by specific regulators and the identification of antimicrobial targets. Targeting the protein-to-protein interfaces of the tripartite assemblies might be an efficacious means to counter drug tolerance; hence, the dynamic process of efflux pump assembly will be an important field to study in the future (Supplementary Box 1) . Regulators that control the stress response, including RNA-mediated regulatory networks, may also represent targets to address in the future for therapeutic intervention.
On reflection, the detailed analysis of efflux systems, from the level of stereochemistry to the intricate interconnections with physiology and host interactions, illustrates the immense regulatory complexity and hidden layers in which these systems contribute to biological function.
Published online 12 July 2018
